Moreover, whilst Prl elicits JAK2-STAT5 signalling and ERK signalling in cancer cells, normal MECs do not produce an ERK response, suggesting that important differences in the regulatory mechanisms controlling PrlR signalling exist in different contexts. This evidence concerns the gene MAPK1 and cancer.